48 results on '"Mantzaris, Gerassimos J."'
Search Results
2. Tu1549: IMPLEMENTATION AND SHORT-TERM ADVERSE EVENTS OF ANTI-SARSCOV-2 VACCINES IN INFLAMMATORY BOWEL DISEASE PATIENTS: AN INTERNATIONAL WEB-BASED SURVEY
3. Tu1551: PATIENTS WITH INFLAMMATORY BOWEL DISEASES HAVE IMPAIRED ANTIBODY PRODUCTION AFTER ANTI-SARS-COV-2 VACCINATION, ESPECIALLY THOSE ON ANTI-TNFα OR COMBINATION TREATMENT OF BIOLOGICS PLUS IMMUNOMODULATORS: RESULTS FROM A PANHELLENIC REGISTRY
4. 22 REAL-WORLD EFFECTIVENESS OF FIRST-LINE BIOLOGIC VEDOLIZUMAB IN CROHN'S DISEASE: ANALYSIS OF HIGHER TREATMENT EFFECT SUBPOPULATION FROM THE EVOLVE STUDY
5. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD
6. Sa1748 CLINICAL EFFECTIVENESS AND SAFETY OF FIRST-LINE BIOLOGIC VEDOLIZUMAB AS A MONOTHERAPY OR COMBINATION THERAPY IN ULCERATIVE COLITIS AND CROHN'S DISEASE PATIENTS: RESULTS FROM THE EVOLVE STUDY
7. Sa1741 A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
8. Mo1811 REAL-WORLD CLINICAL OUTCOMES OF BIOLOGIC-NAÏVE NONCOMPLICATED CROHN'S DISEASE PATIENTS TREATED WITH VEDOLIZUMAB: RESULTS FROM THE EVOLVE STUDY
9. Efficacy of IL12/23 Blockade Expands Our Therapeutic Targets and Challenges the Old Dogma in Ulcerative Colitis
10. Sa1796 – Association Between Use of Antihypertensive Agents and Disease Severity in Patients with Inflammatory Bowel Disease
11. Su1858 – Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF in Biologic-Naive Ulcerative Colitis Patients: Results from the Evolve Study
12. Sa1793 – Evaluation of the 10-Year Cardiovascular Disease Death Risk in Greek Patients with Inflammatory Bowel Disease
13. Mo1905 – A Retrospective Study to Examine the Impact of Crohn’s Disease Duration on Adalimumab’s Effectiveness to Achieve Remission in Patients Bearing Poor Prognostic Factors: the ‘Modify’ Study
14. Su1859 – Real-World Effectiveness and Safety of Vedolizumab and Anti-TNF in Biologic-Naive Crohn’s Disease Patients: Results from the Evolve Study
15. Serum Proteomic Analysis of Patients with Irritable Bowel Syndrome
16. Predictors of Tissue Healing in Ulcerative Colitis Patients Treated with Anti-TNF
17. 19 Infliximab Discontinuation Is Associated With a Higher Risk for Relapse in Patients With Ulcerative Colitis in Remission: A Multinational Collaborative Retrospective Study
18. Su1809 Combining Anti-Inflammatory Treatment With Antiviral Treatment in Severe CMV Positive Ulcerative Colitis Does Not Affect Colectomy Rate: A Retrospective Multicenter Study
19. Tu1962 Looking Beyond Symptoms and Disease Activity to Define Disease Severity in Inflammatory Bowel Disease: Results of an IOIBD Specialist Panel
20. Tu1343 Long-Term Outcome of IBD Patients With Primary Non-Response to Anti-TNF Therapy
21. Tu1239 Outcome of Early Surgery Versus Aggressive Medical Therapy in Patients With Newly Diagnosed Limited Inflammatory/Obstructive (A2/3L1B1/2) Terminal Ileitis: A Two-Year, Prospective, Single-Center, Pilot Study
22. Tu1615 - Serum Proteomic Analysis of Patients with Irritable Bowel Syndrome
23. Sa1895 - Predictors of Tissue Healing in Ulcerative Colitis Patients Treated with Anti-TNF
24. Sa1270 Can We Increase the Dose Interval of Infliximab to 10 Weeks Without Risking Loss of Response in Patients With Crohn's Disease? Prospective, Single-Center Pilot Study Based on Successive Measurements of Fecal Calprotectin
25. Su1393 Primary Non Response to Infliximab in Patients With Inflammatory Bowel Disease
26. Mo1230 Systematic Versus Endoscopy-Driven Treatment With Azathioprine to Prevent Postoperative Ileal Crohn's Disease Recurrence: Interim Results From a Randomized, Multicenter Trial
27. Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC
28. Su1220 Dose Optimization Is Effective in Patients With Ulcerative Colitis Losing Response to Infliximab: A Collaborative Multicentre Retrospective Study
29. Sa1202 Relationships Between Clinical Remission, C-Reactive Protein Normalization and Mucosal Healing in Crohn's Disease: Analyses From the SONIC trial
30. Serum Proteome Profile of Crohn's Disease Patients Treated With Infliximab: A Pilot Study
31. Pilot Study of Adalimumab for Early Prevention and/or Treatment of Post-Operative Endoscopic Recurrence of Crohn's Disease
32. Evolution of Endoscopic Activity Scores in Patients With Crohn's Disease Under Azathioprine and/or Infliximab: A Post-Hoc Analysis of the Sonic Data
33. Short and Long Term Outcome of Infliximab Scheduled Therapy for Acute, Severe Ulcerative Colitis. A Prospective, Open Label, Single-Centre, Two-Year Study
34. Association of Steroid-Free Clinical Remission and Complete Mucosal Healing at 6 Months With Clinical Outcome at 1 Year: A Post-Hoc Analysis of SONIC trial Data
35. S2044 Effect of a Gluten Free Diet on Bone Mineral Density in Patients With Celiac Disease
36. W1175 Intestinal Preparation With Simethicone Plus Polyethlene Glycol Versus Polyethlene Glycol for Small Bowel Capsule Endoscopy
37. 751f One Year Data from the Sonic Study: A Randomized, Double-Blind Trial Comparing Infliximab and Infliximab Plus Azathioprine to Azathioprine in Patients with Crohn's Disease Naive to Immunomodulators and Biologic Therapy
38. W1214 A Prospective, Single-Center Study Assessing the Adherence to Long-Term Anti-TNF Treatment in IBD
39. M1069 A Lyophilized Form of S. Boulardii Enhances the Effect of Omeprazole-Triple Therapy in Patients with Organic or Functional Dyspepsia
40. W1301 Sensitivity and Specificity of a Rapid Fecal Calprotectin Test in Patients with Chronic Non Bloody Diarrhea
41. Does the efficacy of azathioprine wane as time on treatment goes by?
42. A comparison of the effect of budesonide and mesalamine on the quality of life in patients with steroid-dependent Crohn's disease
43. A prospective, randomized trial of azathioprine monotherapy Versus Azathioprine and olsalazine for the maintenance of remission of sterold-dependent ulcerative colitis
44. H. pylori infection in common variable immunodeficiency disease (CVID)
45. Immunohistochemical expression of cytokeratins 7 and 20 in gastric intestinal metaplasia and in Barrett's esophagus
46. Budesonide is superior to mesalazine in maintaining disease remission for patients with steroiddependent Crohn's disease
47. Of ciprofloxacin and ulcerative colitis
48. A prospective, randomized trial of azathioprine monotherapy VersusAzathioprine and olsalazine for the maintenance of remission of sterold-dependent ulcerative colitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.